跳至主要内容
临床试验/NL-OMON51293
NL-OMON51293招募中不适用

Real-time MR imaged treatment with holmium microspheres of patients with primary liver cancer; a single center, interventional, non-randomized, feasibility study - EMERITUS-2

Radboud Universitair Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Diagnosis of hepatocellular carcinoma BCLC stage B or C
  • 2. At least one lesion of 10 mm or more in the longest diameter on
  • contrast-enhanced MRI/CT
  • 3. Patient is eligible for TARE as determined by the tumour board (in Dutch:
  • 4. Patient has a life expectancy of 12 weeks or longer
  • 5. Patient has a WHO performance score of 0-2

排除标准

  • 1. Extrahepatic disease that cannot be targeted during the TARE session
  • (enlarged lymph nodes in the liver hilus are allowed)
  • 2. Radiation therapy, chemotherapy or major surgery within 4 weeks before
  • 3. Serum bilirubin > 2.0 x the upper limit of normal
  • 4. ALAT, ASAT, alkaline phosphatase (AF) > 5x the upper limit of normal
  • 5. Glomerular filtration rate (GFR-MDRD) <35 ml/min
  • 6. Leukocytes <4.0 * 109/L or platelet count <60 * 109/L
  • 7. Significant heart disease that in the opinion of the physician increases the
  • risk of ventricular arrhythmia.
  • 8. Pregnancy or breast feeding
  • 9. Disease with increased chance of liver toxicity, such as primary biliary
  • cirrhosis or xeroderma pigmentosum
  • 10. Patients ineligible to undergo MR-imaging (claustrophobia, metal implants,
  • 11. Portal vein thrombosis of the main branch (more distal branches are allowed)
  • 12. Evidence of clinically relevant, untreated portal hypertension combined
  • with grade 3 oesophageal varices
  • 13. Untreated, active hepatitis
  • 14. Body weight > 150 kg (because of maximum table load)
  • 15. Severe allergy for i.v. contrast (Iomeron, Dotarem and/or Primovist)
  • 16. Lung shunt > 30 Gy, as calculated using scout dose 166Ho SPECT/CT.
  • 17. Uncorrectable extrahepatic deposition of scout dose activity. Activity in
  • the falciform ligament, portal lymph nodes or gallbladder are accepted.
  • 18. Unstable final catheter position due to hepatic artery anatomy, which might
  • lead to dislocation of the catheter during transfer to the MRI.

研究者

相似试验